|
| | Aconitine Basic information |
| Product Name: | Aconitine | | Synonyms: | (1ALPHA,3ALPHA,6ALPHA,14ALPHA,15ALPHA,16BETA)-20-ETHYL-1,6,16-TRIMETHOXY-4-(METHOXYMETHYL)ACONITANE-3,8,13,14,15-PENTOL 8-ACETATE 14-BENZOATE;Aconitine 302-27-2;2H-12,3,6a-Ethanylylidene-7,9-methanonaphth[2,3-b]azocine-4,8,9,11,11a(1H,7H)-pentol, 1-ethyldecahydro-6,10,13-trimethoxy-3-(methoxymethyl)-, 11a-acetate 8-benzoate;Aconitane-3,8,13,14,15-pentol, 20-ethyl-1,6,16-trimethoxy-4-(methoxymethyl)-, 8-acetate 14-benzoate, (1a,3a,6a,14a,15a,16b)-;Aconitane-3,8,13,14,15-pentol, 20-ethyl-1,6,16-trimethoxy-4-(methoxymethyl)-, 8-acetate 14-benzoate, (1alpha,3alpha,6alpha,14alpha,15alpha,16beta)-;20-Ethyl-1α,6α,16β-trimethoxy-14α-benzoyloxy-4-(methoxymethyl)aconitane-3α,8,13,15α-tetrol 8-acetate;20-Ethyl-1α,6α,16β-trimethoxy-4-(methoxymethyl)aconitane-3α,8,13,14α,15α-pentol 8-acetate 14-benzoate;(1ALPHA,3ALPHA,6ALPHA,14ALPHA,15ALPHA,16BETA)-20-ETHYL-1,6,16-TRIMETHOXY-4-(METHOXYMETHYL)ACONITANE-3,8,13,14,15-PENTOL 8-ACETATE 14-BENZOATE | | CAS: | 302-27-2 | | MF: | C34H47NO11 | | MW: | 645.74 | | EINECS: | 206-121-7 | | Product Categories: | Alkaloids;Amines;Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;Amines, Aromatics, Chiral Reagents, Pharmaceuticals, Intermediates & Fine Chemicals | | Mol File: | 302-27-2.mol |  |
| | Aconitine Chemical Properties |
| Melting point | 200-205 °C (dec.) | | alpha | D +17.3° (chloroform) | | Boiling point | 675.12°C (rough estimate) | | density | 1.2181 (rough estimate) | | refractive index | 1.6630 (estimate) | | storage temp. | Refrigerator | | solubility | Soluble in ethanol; | | pka | 5.88(at 25℃) | | form | White to off-white powder. | | color | White | | Water Solubility | Soluble in ethanol. Sparingly soluble in water | | Merck | 13,120 | | CAS DataBase Reference | 302-27-2 | | NIST Chemistry Reference | Aconitine(302-27-2) |
| Hazard Codes | T+,Xi | | Risk Statements | 26/28-36/37/38 | | Safety Statements | 24-45-36-26 | | RIDADR | UN 1544 6.1/PG 1 | | WGK Germany | 2 | | RTECS | AR5960000 | | F | 10-34 | | HazardClass | 6.1(a) | | PackingGroup | I | | Toxicity | LD50 in mice (mg/kg): 0.166 i.v.; 0.328 i.p.; approx 1 orally (Dybing); also reported as LD50 in mice (mg/kg): 1.8 orally, 0.270 s.c.; 0.380 i.p.; 0.12 i.v. (Sato) |
| | Aconitine Usage And Synthesis |
| Description | Aconitum plants (Wu Tou, Ranunculaceae family) have been widely used to treat
various diseases, such as rheumatism, knee pain, herpes zoster, scabies, and other
disorders in China for thousands of years. It was first described in Shen Nong’s
Herbal Classic (the earliest classical work of Chinese herbs). Aconitine is the main
active component in Aconitum plants. | | Chemical Properties | Off-White Solid | | Physical properties | Appearance: solid. Solubility: barely soluble in water and soluble in organic solvents such as chloroform or diethyl ether. Its solubility in water and ethanol are
0.3?mg/mL and 35?mg/mL, respectively. Melting point: 203–204?°C (397–399?°F;
476–477?K). Optical rotation:D+17.3° | | History | Preparations of Aconitum roots are employed in Chinese medicine for analgesic,
antirheumatic, and neurological indications. In the Ming Dynasty, Chinese people
had extracted the aconitine from the Aconitum plants. Aconitine is synthesized by
the Aconitum plants via the terpenoid biosynthesis pathway (MEP chloroplast
pathway) | | Uses | Aconitine occurs to the extent of 0.4–0.8%in dried tuberous roots of aconite or monkshood (Aconitum napellus L. and Ranunculaceae) found in India, North America,and Europe. It is used to produce heartarrhythmia in experimental animals and asan antipyretic agent. | | Uses | anesthetic (gastric), antipyretic, and cardiotoxin | | Uses | Neurotoxin. Activates tetrodotoxin-sensitive Na+ channels, inducing presynaptic depolarization, thus blocking the nerve action potential which, in turn, blocks the release of neurotransmitters and dec
reases the end plate potential at the neuromuscular junction. Aconitine also blocks norepinephrine reuptake. In the heart, aconitine induces ventricular tachycardia after intracoronary injection. In c
ultured ventricular myocytes, aconitine increases the duration of the action potential and induces the appearance of early after depolarization.
Used in producing heart arrhythmia in experimental anim
als. | | Definition | ChEBI: A diterpenoid that is 20-ethyl-3alpha,13,15alpha-trihydroxy-1alpha,6alpha,16beta-trimethoxy-4-(methoxymethyl)aconitane-8,14alpha-diol having acetate and b
nzoate groups at the 8- and 14-positions respectively. | | Indications | Aconitine was previously used as an antipyretic and analgesic. However, the clinical
application of aconitine is limited by its high toxicity. Its lethal dose 50% (LD50) for
mice is 1.8?mg/kg (orally) and 0.308?mg/kg (intraperitoneally). | | Health Hazard | Aconitine is among the most toxic alkaloidsknown. Toxic doses are close to therapeuticdoses, and in humans as little as 2 mgmay cause death (Ferry and Vigneau 1983).An oral lethal dose of 28 mg/kg has alsobeen recorded (NIOSH 1986). The toxicsymptoms at low doses may be excitement,drowsiness, and hypermotility. The first signof poisoning from ingestion is a tingling,burning feeling on the lips, mouth, gums,and throat (Hodgson et al. 1988). This isfollowed by nervous disorders, anesthesia,loss of coordination, vertigo, hypersalivation,nausea, vomiting, and diarrhea. Toxic actionsof aconitine are very rapid. The crystallineform of this compound is much more toxicthan the amorphous aconitine. At a lethaldose, death may result from cardiorespiratoryfailure. Procaine may be an effective antidoteagainst aconitine poisoning. | | Pharmacology | Aconitum was found to have neurotoxin. It could activate tetrodotoxin-sensitive Na+
channels, inducing presynaptic depolarization and blocking the nerve action potential and, in turn, blocking the release of neurotransmitters and decreasing the end
plate potential at the neuromuscular junction. Aconitine was also found to block
norepinephrine reuptake
In the heart, aconitine could induce ventricular tachycardia. In cultured ventricular myocytes, aconitine could induce the appearance of early after depolarization by
increasing the duration of the action potential.
Research with mouse nerve-hemidiaphragm muscle preparation found that aconitine at low concentrations (<0.1?μM) could increase the electrically evoked acetylcholine release causing an induced muscle tension. Action potentials were
generated more often at this concentration. While at higher concentrations
(0.3–3?μM), aconitine could decrease the electrically evoked acetylcholine release,
resulting in a decrease in muscle tension. Under the circumstance with high
concentration (0.3–3?μM) of aconitine, the sodium-ion channels were constantly
activated, and transmission of action potentials was suppressed, leading to the formation of non-excitable target cells or paralysis. | | Clinical Use | In clinic, it can be used for treating and alleviating the symptoms caused by arthritis,
lumbocrural pain, and herpes zoster; however, it is utilized infrequently in clinical
practice due to its obvious side effects
According to a review of different reports of aconite poisoning in human beings,
the following clinical features such as neurological, cardiovascular, and gastrointestinal features were observed. The first symptom of aconitine poisoning appeared
approximately 20?min–2?h after oral intake, and they were paresthesia, sweating,
and nausea, which led to severe vomiting, colicky diarrhea, intense pain, and then
paralysis of the skeletal muscles. Following the onset of life-threatening arrhythmia,
including ventricular tachycardia and ventricular fibrillation, death finally occurred
as a result of respiratory paralysis or cardiac arrest. | | target | P450 (e.g. CYP17) | | Purification Methods | Crystallise it from EtOH, CHCl3 or toluene. [Beilstein 21/6 V 310.] |
| | Aconitine Preparation Products And Raw materials |
|
